Thursday, March 05, 2015 12:59:09 PM
March 5, 2015, 11:50 A.M. ET
We believe that partnership and acquisition (P&A) activity is likely to remain a key feature of newsflow and excess returns for investors in the biopharma industry…We highlight 8 small and mid-cap biopharma companies and 2 larger biopharma companies with attractive assets, identified by a hybrid value/fundamental screen. New names include Aegerion Pharmaceuticals (AEGR), AMAG Pharmaceuticals (AMAG), Hyperion Therapeutics (HPTX), Impax Laboratories (IPXL), Medicines Company (MDCO), Mallinckrodt (MNK), Momenta Pharmaceuticals (MNTA), Mylan (MYL), Perrigo (PRGO), and United Therapeutics (UTHR). Two interesting observations regarding this year’s list: 1) Both Medicine Company and United Therapeutics have appeared on previous lists. We believe this reflects their ongoing undervaluation due to product life-cycle concerns; 2) We believe four of the spec pharma companies on our list are seeking accretive M&A, indicating they may be buyers as well as potentially sold.
http://blogs.barrons.com/stockstowatchtoday/2015/03/05/after-pharmacyclics-whos-next-in-biotech-ma/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM